NK Cells in Therapeutic Approaches for Respiratory Viral Infections
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines, Clinical Advancement, and Associated Immunology".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 368
Special Issue Editor
Special Issue Information
Dear Colleagues,
Respiratory viral infections comprise the deadliest communicable diseases worldwide as demonstrated by the COVID-19 pandemic in 2020, as well as recurrent epidemics of, e.g., influenza A virus. Natural killer (NK) cells are key players in the defense against virus-infected cells. While NK cell-based immunotherapy is currently explored for the treatment of hematological cancer, understanding its role in respiratory viral infections and treatment thereof is yet in its infancy.
NK cells can be identified both in blood and in tissues such as the lung. Upon respiratory viral infection, NK cells infiltrate the lung in high numbers and likely contribute to the host defense against virus-infected cells but may also significantly contribute to lung tissue damage. Current knowledge gaps also include, e.g., how to balance the NK cell response upon immune activation and how NK cells affect the adaptive immune response during respiratory viral infections.
This Special Issue invites articles and reviews linking NK cells to treatment of respiratory viral infections, including but not limited to potential beneficial or harmful effects of NK cells affecting therapy, evaluation of the therapeutic potential of NK cells, specific relevant viral evasion mechanisms, and lung-specific mechanisms affecting the local NK cell response.
Dr. Nicole Marquardt
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viral infection
- NK cells
- lung immunology
- inflammation
- cellular therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
